Get App
Last Updated : May 18, 2020 05:00 PM IST | Source:

Buy Biocon; target of Rs 390: ICICI Direct

ICICI Direct is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 390 in its research report dated May 18, 2020.

Broker Research @moneycontrolcom
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Biocon

Q4FY20 revenues grew 3.4% YoY to Rs 1581 crore (I-direct estimate: Rs 1874 crore) mainly due to 20.8% YoY decline in biologics to Rs 357 crore due to Covid-19 impact. EBITDA margins contracted 621 bps YoY to 20.2% (I-direct estimate: 25.0%) due to a below expected operational performance. EBITDA declined 20.9% YoY to Rs 318.6 crore against I-direct estimate of Rs 467.9 crore. Adjusted net profit fell 42.3% YoY to Rs 123.4 crore (I-direct estimate: Rs 237.1 crore). Delta vis-à-vis EBITDA was due to higher depreciation and tax rate.


We arrive at our revised target price of Rs 390 on an SoTP basis. Despite considering the holding company discount, the stock is still offering decent upside at the current level.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Moneycontrol Ready Reckoner
Now that payment deadlines have been relaxed due to COVID-19, the Moneycontrol Ready Reckoner will help keep your date with insurance premiums, tax-saving investments and EMIs, among others.
Get best insights into Options Trading. Join the webinar by Mr. Vishal B Malkan on May 28 only on Moneycontrol. Register Now!

First Published on May 18, 2020 05:00 pm
Follow us on